(Q35552631)

8 August 2017

1 reference

title

Genetics and the management of women at high risk for breast cancer (English)

1 reference

8 August 2017

Genetics and the Management of Women at High Risk for Breast Cancer (English)

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

genetic predisposition to disease

18 March 2024

main subject

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14530500

18 March 2024

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

18 March 2024

author name string

Betty A. Mincey

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14530500

18 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14530500

18 March 2024

publication date

1 January 2003

1 reference

full work available at URL

8 August 2017

https://academic.oup.com/oncolo/article-pdf/8/5/466/41840163/oncolo_8_5_466.pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14530500

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.8-5-466

18 March 2024

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

https://onlinelibrary.wiley.com/doi/full-xml/10.1634/theoncologist.8-5-466

18 March 2024

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

https://academic.oup.com/oncolo/article-pdf/8/5/466/41840163/oncolo_8_5_466.pdf

18 March 2024

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

18 March 2024

1 reference

8 August 2017

volume

8

1 reference

8 August 2017

issue

5

1 reference

8 August 2017

page(s)

466-473

1 reference

Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease

8 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

The genetic attributable risk of breast and ovarian cancer

18 March 2024

2

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Age at onset as an indicator of familial risk of breast cancer

18 March 2024

4

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium

18 March 2024

5

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Genetic and hormonal risk factors in breast cancer

18 March 2024

6

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Cancer in patients with ataxia-telangiectasia and in their relatives in the nordic countries

18 March 2024

7

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Increased frequency of ATM mutations in breast carcinoma patients with early onset disease and positive family history

18 March 2024

8

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours

18 March 2024

9

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations

18 March 2024

10

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Cancer susceptibility and the functions of BRCA1 and BRCA2

18 March 2024

11

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews

18 March 2024

12

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence

18 March 2024

13

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

A Collaborative Survey of 80 Mutations in the BRCA1 Breast and Ovarian Cancer Susceptibility Gene

18 March 2024

15

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer

18 March 2024

16

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium

18 March 2024

17

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13.

18 March 2024

18

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations

18 March 2024

19

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews

18 March 2024

20

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Cancer risks in BRCA2 mutation carriers

18 March 2024

21

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status

18 March 2024

22

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Effect of Radiotherapy After Breast-Conserving Treatment in Women With Breast Cancer and Germline BRCA1/2 Mutations

18 March 2024

23

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

BRCA-associated breast cancer in young women

18 March 2024

24

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk

18 March 2024

25

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer

18 March 2024

26

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing.

18 March 2024

27

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history.

18 March 2024

28

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2

18 March 2024

29

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Genetic testing for susceptibility to adult-onset cancer. The process and content of informed consent

18 March 2024

30

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing

18 March 2024

31

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Significant contribution of large BRCA1 gene rearrangements in 120 French breast and ovarian cancer families

18 March 2024

32

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium

18 March 2024

33

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results.

18 March 2024

35

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer.

18 March 2024

36

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Efficacy of Bilateral Prophylactic Mastectomy in Women with a Family History of Breast Cancer

18 March 2024

37

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography

18 March 2024

38

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation

18 March 2024

39

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.

18 March 2024

40

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry.

18 March 2024

41

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation

18 March 2024

42

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations

18 March 2024

43

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers

18 March 2024

44

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

18 March 2024

45

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial

18 March 2024

46

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial

18 March 2024

48

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Overview of the main outcomes in breast-cancer prevention trials

18 March 2024

49

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.

18 March 2024

50

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group

18 March 2024

51

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Use of Genetic Testing and Prophylactic Mastectomy and Oophorectomy in Women With Breast or Ovarian Cancer From Families With a BRCA1 or BRCA2 Mutation

18 March 2024

52

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Oral contraceptives and the risk of breast cancer.

18 March 2024

53

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies

18 March 2024

54

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer

18 March 2024

55

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers

18 March 2024

56

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

18 March 2024

57

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-466

18 March 2024

Identifiers

1 reference

8 August 2017

1 reference